Follicular Phase Endocrine Characteristics During Ovarian Stimulation and GnRH Antagonist Co-treatment for IVF; Randomized Trial Comparing Corifollitropin Alfa (Elonva) Initiated on Cycle Day 2 or 4.

NCT01633580 Phase 4 COMPLETED

The purpose of the present study is to analyse if corifollitropin alfa, an agent for prolonged ovarian stimulation, administered from day 4 can be clinically used instead of day 2 onwards for a controlled ovarian hyperstimulation (COH) in an antagonist protocol.

Details

Lead sponsor	Universitair Ziekenhuis Brussel
Phase	Phase 4
Status	COMPLETED
Enrolment	67
Start date	2011-12
Completion	2013-03

Conditions

• Infertility

Interventions

• corifollitropin alfa

Primary outcomes

• Consumption of rFSH at the end of the follicular phase — up to 9 months
  The purpose is to assess the additional need for recFSH in each treatment group

Countries

Belgium